Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Quidde J.; Hegewisch-Becker S.; Graeven U.; Lerchenmueller C. A.; Killing B.; Depenbusch R.; Steffens C. -C.; Lange T.; Dietrich G.; Stoehlmacher J.; Reinacher A.; Tannapfel A.; Trarbach T.; Marschner N.; Schmoll H. -J.; Hinke A.; Al-Batran S. -E.; Arnold D.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

【24h】

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

机译：一线诱导治疗后接受维持治疗的转移性结直肠癌患者的生活质量评估：III AIO KRK 0207期临床试验的预先计划分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: First-line maintenance strategies are a current matter of debate in the management of mCRC. Their impact on patient's health-related quality of life (HRQOL) has not yet been evaluated. The objective of this study was to assess whether differences in HRQOL during any active maintenance treatment compared with no maintenance treatment exist.

机译：背景：一线维护策略是mCRC管理中目前争论的话题。尚未评估其对患者健康相关生活质量（HRQOL）的影响。这项研究的目的是评估与不进行维持治疗相比，在任何积极维持治疗期间HRQOL是否存在差异。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2016年第12期|共9页
作者
Quidde J.; Hegewisch-Becker S.; Graeven U.; Lerchenmueller C. A.; Killing B.; Depenbusch R.; Steffens C. -C.; Lange T.; Dietrich G.; Stoehlmacher J.; Reinacher A.; Tannapfel A.; Trarbach T.; Marschner N.; Schmoll H. -J.; Hinke A.; Al-Batran S. -E.; Arnold D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
colorectal cancer; maintenance treatment; quality of life;

机译：大肠癌;维持治疗;生活质量;

相似文献

外文文献
中文文献
专利

1. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial [J] . Quidde J., Hegewisch-Becker S., Graeven U., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第12期

机译：一线诱导治疗后接受维持治疗的转移性结直肠癌患者的生活质量评估：III AIO KRK 0207期临床试验的预先计划分析
2. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial [J] . Hegewisch-Becker Susanna, Noepel-Duennebacke Stefanie, Hinke Axel, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：含有奥沙利铂和贝伐单抗的一线方案治疗原发性肿瘤位置和RAS / BRAF突变状态的影响：来自AIO KRK0207一线和维持治疗试验的预后因素
3. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial [J] . ModestD.P., LaubenderR.P., StintzingS., Acta oncologica. . 2013,第5期

机译：接受西妥昔单抗联合CAPIRI或CAPOX一线治疗的转移性结直肠癌患者的早期肿瘤缩小：德国AIO KRK 0104试验的分析
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A randomized phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验
7. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC) : results of the AIO KRK 0207 phase III\ua0study [O] . Hegewisch-Becker, Susanna, Arnold, Dirk, Lerchenmufcller, Christian, 2014

机译：标准方法联合使用FP，奥沙利铂（Ox）和Bev作为转移性结直肠癌（mCRC）患者的一线治疗后，采用氟嘧啶（FP）加贝伐单抗（Bev），单独或不进行治疗的维持策略AIO KRK 0207第III阶段\ ua0研究

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

摘要

著录项

相似文献

相关主题

期刊订阅